cisplatin + gemcitabine + vandetanib

This is a combination regimen consisting of three drugs: - **Cisplatin** is a platinum-based chemotherapy agent that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. - **Gemcitabine** is a nucleoside analog that inhibits DNA synthesis, also targeting rapidly dividing cancer cells. - **Vandetanib** is an oral small molecule inhibitor targeting vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and RET tyrosine kinases. Vandetanib disrupts tumor angiogenesis and cell proliferation signaling pathways. The combination has been investigated in early-phase clinical trials for advanced cancers, including non-small cell lung cancer and biliary tract cancers. In phase I studies, the regimen was associated with significant toxicities at certain dose levels and was not always well tolerated[1][9]. The rationale for combining these agents lies in their complementary mechanisms—chemotherapy-induced cytotoxicity paired with targeted inhibition of key oncogenic signaling pathways by vandetanib.